July 8, 2002 — Agilent Technologies Inc. today announced that Abgenix Inc. has evaluated and adopted Agilent’s custom microarray platform for genomic research.
null
Under the terms of the agreement, Abgenix researchers have access to Agilent’s complete printed microarray solution portfolio comprising microarray design services, custom in-situ synthesized oligonucleotide microarrays with SurePrint technology, 48-slide DNA microarray scanner and the Rosetta Resolver Gene Expression Data Analysis System. Abgenix has been qualifying the platform and will now use Agilent’s microarray tools in the development of therapeutic monoclonal antibodies. No further details of the agreement were disclosed.